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A B S T R A C T   
Background: Previous studies of association between exposure to poly- and perfluoroalkyl substances (PFAS) and 
gestational hypertension (GH) and preeclampsia (PE) have shown conflicting results, but most dichotomized 
outcome and did not study continuous blood pressure (BP) changes. 
Objectives: To study the association between PFAS exposure in early pregnancy and maternal BP trajectories in 
pregnancy, gestational hypertension and preeclampsia. 
Methods: 1436 women were enrolled in the Odense Child Cohort in early pregnancy and had a serum sample 
drawn, from which perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), per-
fluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA) and perfluorodecanoic acid (PFDA) were measured 
using LC–MS/MS. Repeated BP measurements through pregnancy and information on PE were obtained from 
hospital files. Adjusted linear mixed models were used to investigate association between PFAS exposure and BP 
trajectory. Associations between PFAS and PE and GH were assessed by Cox proportional hazards model. 
Results: All women had measurable concentrations of PFAS. In all of many comparisons higher PFAS exposure 
(apart from PFHxS) was associated with higher systolic (SBP) and diastolic (DBP) blood pressures, although not 
all were significant, which is unlikely to be due to chance. After adjustment, each doubling in PFOS or PFOA 
exposure was associated with 0.47 mmHg (95% CI: − 0.13; 1.08) and 0.36 mmHg (− 0.19; 0.92) higher SBP; and 
0.58 mmHg (0.13; 1.04) and 0.37 mmHg (− 0.05; 0.79) higher DBP. No clear associations between PFAS 
exposure and PE or GH were found. 
Discussion: The magnitude of the association between PFAS exposure and BP might appear small, statistically 
non-significant and the possible clinical importance low. However, at a population level this may slightly shift 
the distribution of BP towards an increased incidence of GH. If BP increases in pregnancy, it may have long-term 
impact on health not only of the pregnant woman but also of her offspring.   
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1. Introduction 
Pregnancy-induced hypertension (PIH) is a common and severe 
pregnancy complication, encompassing gestational hypertension (GH) 
and preeclampsia (PE). GH is characterized by hypertension (blood 
pressure ≥140/90 mmHg) that occurs after 20 weeks of gestation. The 
new International Society for the Study of Hypertension in Pregnancy 
guidelines define PE as GH accompanied by proteinuria, intrauterine 
growth restriction or other maternal end-organ damage (Brown et al., 
2018). PIH affects 5–10 percent of all pregnancies and is one of the most 
common causes of perinatal and maternal morbidity and mortality 
(Sibai et al., 2005). PIH increases the risk of long-term maternal and 
fetal morbidity, particularly from cardiovascular disease (Wilson et al., 
2003). Risk factors for GH and PE include high maternal age, obesity, 
nulliparity, multiple pregnancy, history of PE or hypertension and use of 
assisted reproductive technology, whereas smoking seems protective 
(Bartsch et al., 2016; Stone et al., 2007). However, hypertensive disor-
ders of pregnancy are heterogenous and the pathogenesis is not fully 
elucidated, although for PE it is suggested that insufficient trophoblastic 
invasion of the uterine spiral arteries plays a role, as do other potential 
intermediate factors like maternal inflammation, oxidative stress and 
endothelial dysfunction (Steegers et al., 2010). 
The role of environmental contaminants in PIH is attracting scientific 
attention. Exposure to perfluoroalkyl substances (PFAS) may increase 
susceptibility to PIH (Blake and Fenton 2020). PFAS are persistent 
chemicals with endocrine disrupting properties and long elimination 
half-lives of 4 to 8 years depending on their chemical structure (EFSA 
Panel on Contaminants in the Food Chain (EFSA CONTAM Panel); Dieter 
Schrenk 2020). They are widely used in the industrial and commercial 
production of water-resistant or repellent fabrics, non-stick coatings, 
grease proof materials and as flame retardants (EFSA Panel on Con-
taminants in the Food Chain (EFSA CONTAM Panel); Dieter Schrenk 
2020). Humans are exposed to these substances in everyday life through 
ingestion of contaminated drinking water and food and inhalation of 
indoor air particles (EFSA Panel on Contaminants in the Food Chain 
(EFSA CONTAM Panel); Dieter Schrenk 2020). PFAS are detectable in 
almost all human serum-samples (EFSA Panel on Contaminants in the 
Food Chain (EFSA CONTAM Panel); Dieter Schrenk 2020), especially 
perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) 
used for decades. They are being phased out from most industries (EFSA 
Panel on Contaminants in the Food Chain (EFSA CONTAM Panel); Dieter 
Schrenk 2020). However, the use of newer PFAS including per-
fluorohexane sulfonic acid (PFHxS), perfluorononanoic acid (PFNA) and 
perfluorodecanoic acid (PFDA) are increasingly leading to continued or 
even increased human exposure (EFSA Panel on Contaminants in the 
Food Chain (EFSA CONTAM Panel); Dieter Schrenk 2020). 
Although some previous studies have detected associations between 
PFAS exposure and GH, the results have been conflicting (Avanasi et al., 
2016; Borghese et al., 2020; Darrow et al., 2013; Huang et al., 2019; Huo 
et al., 2020; Nolan et al., 2010; Rylander et al., 2020; Savitz et al., 2012; 
Starling et al., 2014; Stein et al., 2009; Wikstrom et al., 2019). Part of the 
apparent discrepancy is due to differences in exposure levels, different 
mixtures, and different study designs, with exposure imprecision. A 
recent Canadian birth cohort study found no association between PFOA 
or PFOS exposure and GH or PE, however, PFHxS exposure was asso-
ciated with PE, and the effect was more pronounced among women 
carrying a female fetus, whereas women carrying a male fetus had 
higher risk of GH (Borghese et al., 2020). In addition, higher concen-
trations of PFAS were associated with increases in blood pressure in each 
trimester. Most other previous studies, although prospective, only 
recorded BP and diagnosed PE once during pregnancy and dichotomized 
outcome and did not study continuous BP changes, which may result in 
loss of power (Huo et al., 2020; Rylander et al., 2020; Starling et al., 
2014; Wikstrom et al., 2019). 
In the Odense Child Cohort, we had access to data on repeated blood 
pressure (BP) measures and clinical information on the onset of PE, as 
well as measurements of PFAS in early pregnancy among 1436 women. 
We therefore studied the association between PFAS exposure in early 
pregnancy and maternal blood pressure trajectories in pregnancy, 
gestational hypertension and preeclampsia. Finally, we investigated 
whether these effects were modified by pre-pregnancy maternal weight, 
parity and fetal sex. 
2. Materials and methods 
2.1. Study population 
Data from the Odense Child Cohort, a prospective population-based 
cohort from the municipality of Odense, Southern Denmark was used. 
Eligible women were residing in the municipality of Odense, Region of 
Southern Denmark and were recruited at the first antenatal visit (be-
tween 8 and 16 completed gestational weeks (GW)) between 2010 and 
2012. Study aims, design and participants have been described in detail 
previously (Kyhl et al., 2015). Anthropometric data (age, height and pre- 
pregnancy weight and body mass index (BMI)), parity and smoking 
status were derived from hospital records. Educational level (high 
school or less, high school + 1–4 years, high school+ >4 years) was 
extracted from questionnaires, and missing data were retrieved from 
hospital records. 
The present study included all singleton pregnancies with at least 
one BP measurement in pregnancy and PFAS concentrations measured 
in 1st trimester, resulting in 1436 women eligible for the analyses 
(Fig. 1, supplemental Table 1). Maternal BP in pregnancy was measured 
as clinical routine, using appropriate cuff size by a general practitioner 
or a midwife. Maternal pregnancy complications were defined as fol-
lows: Gestational hypertension (GH) was characterized as de novo BP >
140/90 mm Hg after 20 weeks of gestation on two or more episodes with 
at least 4 h in between or significant aggravation of pre-existing hy-
pertension, preeclampsia (PE) as GH with proteinuria (>0.3 g/24 h or at 
least + 1 on sterile urine dipstick) according to the Danish Society of 
Obstetrics and Gynecology diagnostic criteria of hypertension and pre-
eclampsia 2007–2012 (Luef et al., 2016). PIH encompassed GH and PE. 
Diagnoses of GH and PE were validated by a person reviewing all hos-
pital files and all BP measurements in pregnancy collected by a retro-
spective evaluation of the electronic patient files and hand-written 
maternity health charts (Birukov et al., 2020; Luef et al., 2016). 
2.2. PFAS measurements 
Serum samples obtained at inclusion at GA 8–16 weeks from 1699 
women were analyzed for concentrations PFHxS, PFOS, PFOA, PFNA 
and PFDA using online solid phase extraction followed by liquid chro-
matography and triple quadropole mass spectrometry (LC–MS/MS) at 
Department of Environmental Medicine, University of Southern 
Denmark (Vorkamp et al., 2014). Of the samples, 199 were analyzed in 
2011, further 330 were analyzed in 2013, 191 in 2014 and the 
remaining 979 in 2019. The within-batch coefficients of variation (CVs) 
were <3% and the between batch CVs, for all sets analyzed were 
<10.5% (Beck et al., 2019). The limit of quantification (LOQ) was 0.03 
ng/ml for all compounds. PFOS, PFOA, PFNA and PFDA were 100% 
quantifiable, whereas PFHxS were quantifiable in 98% of samples. 
2.3. Ethical approval 
All participating women provided written informed consent. The 
study has been approved by the Regional Scientific Ethical Committees 
for Southern Denmark (no. S-20090130) and the Data Protection Agency 
(j.no. 2008-58-0035). 
2.4. Statistical analysis 
Normally distributed data were reported as means with 
A. Birukov et al.                                                                                                                                                                                                                                
Environment International 151 (2021) 106442
3
corresponding standard deviation, SDs, non-normally distributed data 
as medians with interquartile ranges. PFAS were not normally distrib-
uted and were log2-transformed to allow assessment of the relative 
change in the outcome parameters for a doubling of exposure. We used 
descriptive statistics to inspect distributions of explanatory variables for 
both GH and PE. The maternal BP trajectory consisted of longitudinally 
collected BP data, which was structured in four-week intervals. Crude 
and adjusted linear mixed models based on random intercept with 
variance components covariance structure were used to investigate 
prospective relationships between maternal 1st trimester PFAS exposure 
(log2-transformed) and BP trajectory as continuous outcome as previ-
ously described (Birukov et al., 2020). In brief, linear mixed models (also 
called hierarchical linear models or multilevel models) account for intra- 
individual autocorrelations or missing data resulting from longitudinal 
repeated measurements on the same subjects. Fixed effects in the 
adjusted linear models included log-transformed PFAS, pre-pregnancy 
BMI, maternal age, smoking status and parity. We also stratified the 
analyses for BP and PE by fetal sex, parity and BMI as these parameters 
may modify the associations (Jensen et al., 2018). Effect modification 
was evaluated by construction of interaction terms on multiplicative 
scale and evaluation of significance level. In addition, we performed a 
sensitivity analysis in women with at least three available BP measure-
ments. Associations between PFAS and the incidence of PIH, GH and PE 
were assessed by Cox proportional hazards model. The same confounder 
structure as in linear mixed models was used in the Cox models, as these 
factors can modify the a-priori risk for PE and were associated with PFAS 
exposure (Table 1) (Bartsch et al., 2016). 
In the Cox analyses, follow-up of pregnant women began at the date 
of 1st trimester blood sampling and ended with censoring at the date of 
an event (PE, GH) or uneventful delivery. Restricted cubic splines were 
used to assess potential non-linearity in the relationships between PFAS 
concentration and PE incidence with median PFAS values as reference 
and knots at the 5th, 50th and 95th percentiles. 
All statistical analyses were carried out in R version 4.0.2 and SAS 
(version 9.4, Enterprise Guide 7.1, SAS Institute Inc., Cary, NC, USA). A 
two-sided p-value <0.05 was considered statistically significant. 
3. Results 
A total of 1436 women were included (Fig. 1). The vast majority 
were Caucasian (96.1%), their mean age was 30.3 years (4.5), and their 
mean BMI was 24.3 kg/m2 (4.4). Most of the participants had 1 to 4 
years post high-school educational background (50.2%), 5.0% of the 
women were smokers before pregnancy (Table 1). The total prevalence 
of GH and PE was 3.4% (N = 49/1436) and 7.2% (N = 104/1436) 
respectively. Mean SBP and DBP in the first, second and third trimesters 
were 116.4 (10.8), 116.0 (10.1), 121.0 (9.21) mmHg for SBP and 71.4 
(8.69), 70.8 (7.67), 76.0 (7.01) mmHg for DBP (Table 1). Women with 
PE and GH had higher pre-pregnancy BMI and were more often nullip-
arous (Table 1). The blood pressure trajectory of women with PE and GH 
was elevated throughout pregnancy, starting as early as the 1st trimester 
as shown in previously published data from the Odense Child Cohort 
(Birukov et al., 2020). A total of 152 women (10.6%) had <3 BP mea-
surements, 1021 (71.1%) between 3 and 6, and 263 (18.3%) >6 BP 
measurements during pregnancy (Suppl Table 1). 
Median concentrations of PFHxS, PFOS, PFOA, PFNA, PFDA and 
PFOS were 0.4, 7.5, 1.7, 0.6 and 0.3 ng/ml, respectively (Table 1). PFAS 
were moderately to strongly intercorrelated (Spearman correlation co-
efficients between 0.30 and 0.67). Younger, smoking, normal-weight, 
nulliparous women had higher median serum concentrations of PFAS 
(Jensen et al., 2018). 
Women with higher PFOS, PFOA, PFNA, PFDA exposure generally 
had higher SBP and DBP both in the unadjusted and adjusted models 
(Table 2), whereas PFHxS exposure was associated with reduced blood 
pressure. These associations were statistically significant for PFOS 
exposure and DBP and PFHxS exposure and SBP. After adjustment for 
age, pre-pregnancy BMI, parity and smoking status, each doubling in 
PFOS exposure was associated with 0.47 mmHg (95% CI: − 0.13; 1.08) 
higher SBP and 0.58 mmHg (0.13; 1.04) higher DBP. Each doubling of 
PFHxS exposure was associated with a significant reduction of − 0.51 
mmHg (− 0.97; − 0.04) in SBP and − 0.30 mmHg (− 0.65; 0.06) in DBP. 
Generally, no clear associations were found between PFAS exposure and 
PE, GH or PIH (Table 3) in Cox regressions, and no non-linear associa-
tions between exposure to PFAS and PE could be detected after 
Fig. 1. Flow chart for the included 1436 women from the Odense Child Cohort.  
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inspection of restricted cubic splines (Fig. 2). Sensitivity analyses among 
women with at least three available BP measurements showed associa-
tions within the same direction and magnitude (data not shown). 
No clear differences in blood pressure were found between women 
carrying a male or a female fetus and being exposed to PFAS (Suppl 
Table 2), and no significant interaction with fetal sex for any PFAS (all p- 
values for interaction >0.05) was seen. However, there was a significant 
interaction between PFOA and maternal overweight status (p- 
interaction with SBP p = 0.02 and with DBP p = 0.04), PFOA associated 
with higher BP only in normal-weight women, (suppl Table 3), while in 
overweight women the tendency went in the opposite direction. Like-
wise, PFDA and PFNA exposure was associated with higher BP in normal 
weight women compared to overweight women, whereas PFOS expo-
sure had higher impact in overweight women (Suppl Table 3). No clear 
difference in BP and PE among nulli- and multiparous women exposed to 
PFAS was found, though PFOS significantly and positively associated 
with SBP and DBP trajectories in nulliparous women (p-interaction for 
SBP and DBP p = 0.02) (Suppl Table 4). 
4. Discussion 
In this large prospective cohort study, we found that first trimester 
exposure to PFAS was associated with slightly higher blood pressure in 
pregnancy. Exposure to four out of five PFAS was associated with higher 
BP in all analyses, though not all were statistically significant, and we 
therefore consider it unlikely that the findings are due to chance. PFHxS 
exposure was associated with a reduction in blood pressure, and since 
we have no biological explanation for this, we consider this a chance 
finding. We did not find any significant association between PFAS 
exposure and preeclampsia nor with GH or PIH. 
The magnitude of the observed effects might appear small at first 
glance, and a doubling of exposure seems considerable, however, the 
variation in PFAS exposure was large, with >6 times higher exposure 
among high compared to low exposed women. The clinical significance 
of these findings might not impact the anticipated pregnancy outcome of 
the individual women. Yet, at a population level, this tendency could 
slightly shift the distribution of blood pressure towards an increased 
incidence of gestational hypertension. In addition, higher blood pressure 
in pregnancy is associated with poorer long-term cardiovascular health 
of both the mother and child (Birukov et al., 2020), and a recent pro-
spective study suggested that pregnancy concentrations of PFAS were 
associated with adverse postpartum cardiometabolic markers including 
blood pressure three years postpartum (Mitro et al., 2020). Our findings 
highlight the importance of using continuous outcome measures in 
healthy participants instead of dichotomizing into healthy versus non- 
healthy participants. By dichotomizing BP measurements, the study 
power is reduced, the extent of variation in outcome measures is 
underestimated between healthy and diseased groups, and the impact of 
the findings is limited to identifying risk factors for diseases. 
Only one previous study used continuous blood pressure measures, 
like we did, and generally found that PFOS, PFOA and PFHxS exposure 
was associated with increase in DBP and for PFOA and PFHxS also for 
SBP in the same magnitudes as ours, though not all were statistically 
significant (Borghese et al., 2020). We found lower blood pressure 
among PFHxS exposed women, discrepancies may be due to the fact that 
PFHxS exposure was much higher among Canadian compared to Danish 
women. The Canadian study found higher risk of PE among women 
exposed to PFAS and carrying a female fetus, findings which we could 
not confirm. They did not measure PFNA or PFDA and only measured 
blood pressure three times during pregnancy, while we included up to 9 
measures per woman, after averaging blood pressure measurements in 4 
weeks intervals. 
The epidemiological evidence for the associations between PFAS and 
GH and PE relies on different study designs and possible variability in 
both exposure assessment and the outcome assessment, possibly there-
fore findings are mostly null and weak positive findings (Avanasi et al., 
2016; Borghese et al., 2020; Darrow et al., 2013; Huang et al., 2019; Huo 
et al., 2020; Nolan et al., 2010; Rylander et al., 2020; Savitz et al., 2012; 
Starling et al., 2014; Stein et al., 2009; Wikstrom et al., 2019). Most 
studies examined PE only, and few studied GH. A population of pregnant 
women from the Mid-Ohio Valley region has been studied, they were 
exposed to high levels of PFOA through contaminated drinking water 
(Darrow et al., 2013; Nolan et al., 2010; Savitz et al., 2012; Stein et al., 
2009). They found both positive and negative associations, however, 
Table 1 
Characteristics of the 1436 pregnant women in the Odense Child Cohort ac-





No PE or GH 
N = 1283 
(89.3%) 
GH 
N = 49 
(3.4%) 
PE 
N = 104 
(7.2%) 
Age (years) 30.3 (4.45) 30.3 (4.45) 30.9 (3.89) 30.2 (4.74) 
<25 318 (19.7) 130 (10.1) 1 (2.0) 11 (10.6) 
25–34 1031 (64.0) 920 (71.7) 40 (81.6) 71 (68.3) 
>34 263 (16.3) 233 (18.2) 8 (16.3) 22 (21.2) 
Prepregnancy 
BMI (kg/m2) 
24.3 (4.38) 24.0 (4.02) 26.1 (5.96) 26.9 (6.33) 
<20 339 (21.0) 150 (11.7) 6 (12.2) 7 (6.7) 
20–25 787 (48.8) 726 (56.6) 18 (36.7) 43 (41.4) 
>25 486 (30.2) 407 (31.7) 25 (51.0) 54 (51.9) 
Maternal 
education     
High school 
or less 
413 (29.1) 362 (28.8) 14 (28.6) 36 (34.6) 
High school 
+ 1–4 years 
712 (50.2) 636 (50.5) 22 (44.9) 52 (50.0) 
High school 
+ > 4 years 
292 (20.6) 261 (20.7) 13 (26.5) 16 (15.4) 
Parity     
Nulliparous 808 (56.3) 693 (54.0) 36 (73.5) 79 (76.0) 
Multiparous 628 (43.7) 590 (46.0) 13 (26.5) 25 (24.0) 
Smoking     
No 1364 (95.0) 1221 (95.2) 46 (93.9) 97 (93.3) 







118.9 (8.60) 117.7 (7.83) 130.7 (6.58) 127.9 (9.05) 
First 
trimester 
116.4 (10.8) 115.7 (10.2) 124.6 (12.4) 121.4 (13.6) 
Second 
trimester 
116.0 (10.1) 114.8 (9.43) 126.9 (11.8) 123.8 (10.5) 
Third 
trimester 







73.9 (6.61) 73.0 (5.94) 82.7 (5.30) 81.4 (7.20) 
First 
trimester 
71.4 (8.69) 70.8 (8.37) 77.9 (8.36) 75.9 (10.1) 
Second 
trimester 
70.8 (7.67) 70.0 (7.13) 78.2 (8.15) 76.7 (8.89) 
Third 
trimester 
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findings may not be generalizable to other populations. Three cohort 
studies of general obstetric populations have demonstrated conflicting 
results between PFAS exposure and PE (Borghese et al., 2020; Huo et al., 
2020; Wikstrom et al., 2019). Differences in timing of PFAS measure-
ment as well as exposure levels and definition of PE limits comparability. 
Two case-control studies (Rylander et al., 2020; Starling et al., 2014) 
found no association between PFAS exposure and PE, however, PE di-
agnoses were obtained from registers. Likewise, a Chinese study found 
no association between cord blood PFAS concentrations and PE, how-
ever cord blood may not be a good marker of early pregnancy exposure 
(Huang et al., 2019). Two studies have examined the impact of PFAS 
exposure on GH and found no clear associations, which is in accordance 
with our findings (Borghese et al., 2020; Huo et al., 2020). Overall, our 
study suggests that PFAS exposure in pregnancy may increase blood 
pressure, whereas the effect on PE is limited. 
Mechanisms behind an association between PFAS exposure and 
blood pressure are yet to be resolved, but the concerns about immuno-
logic effects from PFAS may be considered (EFSA Panel on Contaminants 
in the Food Chain (EFSA CONTAM Panel); Dieter Schrenk 2020). The 
vascular disturbances, which play a key role in PE development, include 
endothelial dysfunction that is in turn associated with oxidative stress 
and increased inflammatory response (EFSA Panel on Contaminants in 
the Food Chain (EFSA CONTAM Panel); Dieter Schrenk 2020). Oxidative 
stress is the key mechanism of arterial damage and endothelial 
dysfunction, which promote increases in blood pressure, vascular dis-
ease and arterial stiffness. Given that PFOS have been shown to induce 
Table 2 
Unadjusted and adjusted* β coefficients and 95% confidence intervals (95% CI) from linear mixed models for 1st trimester PFAS in regard to gestational systolic and 
diastolic blood pressures (SBP and DBP) trajectories among 1436 women. Associations are shown as change in mm Hg per doubling in PFAS concentrations.  
Doubling of PFAS (ng/ml) Unadjusted β coefficients (95% CI) Adjusted* β coefficients (95% CI) 
SBP trajectory (mmHg) p- 
value 
DBP trajectory (mmHg) p- 
value 
SBP trajectory (mmHg) p- 
value 
DBP trajectory (mmHg) p- 
value 
PFHxS − 0.17 (− 0.65; 0.30) 0.48 − 0.08 (− 0.44; 0.29) 0.69 − 0.51 (− 0.97; − 0.04) 0.03 − 0.30 (− 0.65; 0.06) 0.10 
PFOS 0.72 (0.09; 1.34) 0.02 0.73 (0.24; 1.21) <0.01 0.47 (− 0.13; 1.08) 0.13 0.58 (0.13; 1.04) 0.01 
PFOA 0.78 (0.25; 1.31) <0.01 0.61 (0.20; 1.02) <0.01 0.36 (− 0.19; 0.92) 0.20 0.37 (− 0.05; 0.79) 0.08 
PFNA 0.32 (− 0.33; 0.97) 0.34 0.23 (− 0.28; 0.73) 0.38 0.19 (− 0.44; 0.82) 0.55 0.18 (− 0.29; 0.66) 0.45 
PFDA − 0.22 (− 0.79; 0.36) 0.46 − 0.19 (− 0.64; 0.25) 0.39 0.07 (− 0.48; 0.61) 0.80 0.08 (− 0.33; 0.49) 0.70 
*Adjusted for maternal age, pre-pregnancy BMI, parity and smoking status. 
Table 3 
Adjusted* hazard ratios and 95% confidence intervals (95% CI) between 1st 
trimester PFAS and pregnancy induced hypertension (PIH), gestational hyper-
tension (GH) and preeclampsia (PE). Associations are shown as HR per doubling 
in PFAS concentrations.  
Doubling of 
PFAS (ng/ml) 
Adjusted* hazard ratio (95% CI) 
PIH 





























































*Adjusted for maternal age, pre-pregnancy BMI, parity and smoking. 
Fig. 2. Restricted cubic splines assessing potential non-linearity in the relationships between preeclampsia and PFAS.  
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oxidative stress in human endothelial cells (EFSA Panel on Contami-
nants in the Food Chain (EFSA CONTAM Panel); Dieter Schrenk 2020) 
and the support for immune system changes to PFOS exposure, we can 
only speculate on pathways involving oxidative stress and inflammation 
behind the present associations. There is some toxicological evidence to 
support the potential for fetal-sex specific effects of prenatal exposure to 
PFAS through the inhibition of aromatase activity within human 
placental trophoblastic cells (Gorrochategui et al., 2014), but further 
toxicological evidence is required to better understand any potential 
fetal sex-specific effects. 
A major strength of our study is the population-based design in a low- 
risk setting of Danish women. However, only 42% of the eligible preg-
nant women participated in the Odense Child Cohort, and they were 
more likely to be non-smokers, older and nulliparous than non- 
participants (Kyhl et al., 2015). Diagnoses of GH and PE (3.4% and 
7.2%) were higher than in the general Danish population probably 
partly explained by the few smokers and the fact that diagnoses were 
validated by medical chart review for all participants (Luef et al., 2016). 
A population-based US cohort study found that the discharge diagnoses 
of PE reported to the national patient registry substantially under-
estimated the true prevalence as detected by retrospective patient chart 
review (Geller et al., 2004). In addition, the women were unaware of 
their PFAS exposure, so this is unlikely to have affected their partici-
pation. Since we compared women across PFAS exposure, whether they 
represent the general population is of less importance. Further strengths 
are multiple BP measurements over the course of entire pregnancy, 
prospective study design, extensive adjustments for confounders and 
effect modification analyses. Moreover, we measured several PFAS in 
one setting, which allowed us to perform comparative analyses of 
exposure to several PFAS. 
Limitations include the observational nature of associations. We did 
not have information about women with hypertension before preg-
nancy, but we expect the number to be low and possibly dilute our 
findings toward an underestimation of the risk. Furthermore, our study 
data are derived from BP measurements in pregnancy collected at 
routine visits with a midwife or general practitioner and therefore not 
standardized according to protocol e.g. same equipment, rest periods or 
three independent measures. However, we would expect that the mea-
surement error would be random, and thus could potentially dilute our 
findings rather than introducing a systematic bias. In addition, serum 
concentrations of PFAS were measured in early pregnancy before the 
outcomes, as they are known to decrease throughout pregnancy, likely 
due both to foetal transfer and to dilution as a result of increased 
maternal blood volume during pregnancy (Bach et al., 2015). Still, PFAS 
measurements at different timepoints during pregnancy are highly 
intercorrelated, and the major compounds have long half-lives of 4–5 
years (EFSA Panel on Contaminants in the Food Chain (EFSA CONTAM 
Panel); Dieter Schrenk 2020). The exposure level reflected by the serum 
concentration was therefore believed to be representative of the expo-
sure during the entire pregnancy. PFOA and PFOS exposure had the 
highest impact on BP and PE in pregnancy but also appeared in the 
highest concentrations. To what extent other PFAS contribute to this 
tendency is difficult to determine due to the intercorrelations between 
the substances, and we did not study mixture effects and cannot deci-
pher the individual contribution of single PFAS. 
A recent publication from the European Food Safety Authority 
(EFSA) has highlighted the lack of data on PFAS and blood pressure not 
only in pregnancy but across the whole life perspective (EFSA Panel on 
Contaminants in the Food Chain (EFSA CONTAM Panel); Dieter Schrenk 
2020), and some studies in non-pregnant individuals have suggested 
association between PFAS exposure and blood pressure (Lin et al., 2020; 
Min et al., 2012). Our findings support that even in this relatively low- 
level exposed population of pregnant women, exposure to PFAS may 
increase blood pressure and possibly impact future health of both 
mother and child (Birukov et al., 2020; Wilson et al., 2003). 
In conclusion, in this large prospective cohort study, we found 
associations between first-trimester exposure to four out of five PFAS 
and modest increases in blood pressure in pregnancy in all different 
analyses although only significant for PFOS. No clear association be-
tween PFAS exposure and preeclampsia was found. At population level, 
this tendency could slightly shift the distribution of blood pressure to-
wards an increased incidence of gestational hypertension and therefore 
highlight the importance of using continuous outcome measures instead 
of formal diagnoses. Our findings are of general public interest, as all 
pregnant women were exposed to these chemicals, and if blood pres-
sures increase in pregnancy, it may have long-term impact on health not 
only for the women but also for their children. 
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